四川医学
四川醫學
사천의학
SICHUAN MEDICAL JOURNAL
2015年
6期
791-794
,共4页
党运芝%吕博%李鑫%刘隽悦%周咏春%李围围%张莹%李剑平%魏丽春
黨運芝%呂博%李鑫%劉雋悅%週詠春%李圍圍%張瑩%李劍平%魏麗春
당운지%려박%리흠%류준열%주영춘%리위위%장형%리검평%위려춘
宫颈癌%顺铂%多西他赛联合顺铂(TP)
宮頸癌%順鉑%多西他賽聯閤順鉑(TP)
궁경암%순박%다서타새연합순박(TP)
cervical cancer%cisplatin%cispaltin plus docetaxel
目的:比较宫颈癌放化同期治疗过程中,顺铂单药每周方案与多西他赛联合顺铂( TP)方案化疗的急性毒性反应。方法回顾性分析2013年1月至2015年3月,我科收治的180例IB-IVB宫颈癌患者,放疗采用3-DCRT或IM-RT技术,1次/d,每周5次。化疗方案如下,顺铂单药组:共81例,化疗剂量40mg/m 2,每周1次,放疗期间化疗5~6周期;TP组:共计99例,多西他赛:60mg/m 2,注射用顺铂60mg/m 2,每3周1次,放疗期间化疗2周期。结果血液学毒性:顺铂单药组,32例患者出现Ⅲ-Ⅳ度骨髓抑制(39.5%);而TP组30例(30.3%),两组患者骨髓抑制发生率及严重程度差异无统计学意义(P=0.192)。而TP组患者的下消化道及泌尿系毒性均高于顺铂单药组。两组患者在放疗总时间差异无统计学意义,两组患者的初步疗效相似(P=0.92,1.0)。结论与单药顺铂每周方案相比,TP方案化疗并没有增加急性毒副反应,患者的耐受性较好。
目的:比較宮頸癌放化同期治療過程中,順鉑單藥每週方案與多西他賽聯閤順鉑( TP)方案化療的急性毒性反應。方法迴顧性分析2013年1月至2015年3月,我科收治的180例IB-IVB宮頸癌患者,放療採用3-DCRT或IM-RT技術,1次/d,每週5次。化療方案如下,順鉑單藥組:共81例,化療劑量40mg/m 2,每週1次,放療期間化療5~6週期;TP組:共計99例,多西他賽:60mg/m 2,註射用順鉑60mg/m 2,每3週1次,放療期間化療2週期。結果血液學毒性:順鉑單藥組,32例患者齣現Ⅲ-Ⅳ度骨髓抑製(39.5%);而TP組30例(30.3%),兩組患者骨髓抑製髮生率及嚴重程度差異無統計學意義(P=0.192)。而TP組患者的下消化道及泌尿繫毒性均高于順鉑單藥組。兩組患者在放療總時間差異無統計學意義,兩組患者的初步療效相似(P=0.92,1.0)。結論與單藥順鉑每週方案相比,TP方案化療併沒有增加急性毒副反應,患者的耐受性較好。
목적:비교궁경암방화동기치료과정중,순박단약매주방안여다서타새연합순박( TP)방안화료적급성독성반응。방법회고성분석2013년1월지2015년3월,아과수치적180례IB-IVB궁경암환자,방료채용3-DCRT혹IM-RT기술,1차/d,매주5차。화료방안여하,순박단약조:공81례,화료제량40mg/m 2,매주1차,방료기간화료5~6주기;TP조:공계99례,다서타새:60mg/m 2,주사용순박60mg/m 2,매3주1차,방료기간화료2주기。결과혈액학독성:순박단약조,32례환자출현Ⅲ-Ⅳ도골수억제(39.5%);이TP조30례(30.3%),량조환자골수억제발생솔급엄중정도차이무통계학의의(P=0.192)。이TP조환자적하소화도급비뇨계독성균고우순박단약조。량조환자재방료총시간차이무통계학의의,량조환자적초보료효상사(P=0.92,1.0)。결론여단약순박매주방안상비,TP방안화료병몰유증가급성독부반응,환자적내수성교호。
Objective To compare the acute side effects and feasibility of cocurrent chemoradiotherapy with cisplatin or with cispaltin plus docetaxel in the treatment of local advanced cervical cancer. Methods Between January 2013 and March 2014, 180 pa-tients with FIGO IB-IVB cervical cancer were analyzed. All patients in this study were treated with 3D-CRT (three-dimensional confor-mal radiotherapy) or IMRT (intensity modulated radiotherapy) external beam radiation therapy techniques through a 6 MV photon. The arm A received 5-6 cycles of cisplatin at a dose of 40 mg/m 2 , weekly. The arm B received 2cycles of docetaxel 60mg/m2 plus cisplatin 60mg/m2. Result Grade III–IV neutropenia occurred in 39. 5% in arm A and 30. 5% in the patients of arm B (P=0. 192). The arm B presented higher lower digestive tract and urinary system complications rate. However, the overall radiotherapy time and primary response rate were similar in two group(P=0. 192). Conclusion Cocurrent chemoradiotherapy with cispaltin plus docetaxel had similar acute side effect and can be well tolerated compared with cisplatin.